๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Platinum-resistant Ovarian Cancer
Clinical trial register · United States · industry-sponsored

Platinum-resistant Ovarian Cancer Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 8 New York 6 Florida 6 Michigan 5 Massachusetts 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
ImmunityBio, Inc.1 Context Therapeutics Inc.1 Ascendis Pharma Oncology Division A/S1 NextCure, Inc.1 Genelux Corporation1
State
California8 New York6 Florida6 Michigan5 Massachusetts4
All 32 states
Target enrolment
to
14 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
NCT07226427Platinum-resistant Ovarian Cancer
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Active, closed
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NCT07109414Platinum-resistant Ovarian Cancer
Novita Pharmaceuticals, Inc.
Phase 2/3
380
Arizona, Louisiana, New Mexico, Pennsylvania, Utah, Wisconsin
2025-12-29
Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
Michigan, Minnesota, New York, Texas
2025-06-16
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
MacroGenics
Phase 2
80
California, Louisiana, Michigan, Pennsylvania, Texas, Wisconsin
2025-05-01
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
Genmab
Phase 3
530
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288Platinum-resistant Ovarian Cancer
ImmunityBio, Inc.
Phase 2
20
California
2024-11-06
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Recruiting
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05281471Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Genelux Corporation
Phase 3
186
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Michigan
2022-08-31
Active, closed
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
TILT Biotherapeutics Ltd.
Phase 1/2
29
Minnesota, New York
2022-05-17
Active, closed
A Study to Investigate Safety and Tolerability of TransCon IL-2 ฮฒ/ฮณ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
Ascendis Pharma Oncology Division A/S
Phase 1/2
320
California, Illinois, Kentucky, Massachusetts, New Jersey, New York, North Carolina, Ohio
2022-01-11
Active, closed
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
NCT03949283Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Cordgenics, LLC
Phase 3
150
California, Florida, Louisiana, Ohio, Oklahoma, Pennsylvania, West Virginia
2019-07-26
Active, closed
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
NCT03319628Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Mersana Therapeutics
Phase 1/2
523
Oklahoma
2017-12-12
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/platinum-resistant-ovarian-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.